Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review

Bonde, Jesper; Bottari, Fabio; Iacobone, Anna Daniela; Cocuzza, C; Sandri, Maria-Teresa; Bogliatto, Fabrizio; Khan, Khalid S.; Ejegod, Ditte Møller; Gary, Devin S.; Andrews, Jeffrey C

doi:10.1097/lgt.0000000000000573

Cited by 25 publications

(26 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of possibly carcinogenic HPV types and HPV genotyping in the FDA-approved assays makes it difficult to differentiate between women with same genotype persistence and genotype switch. Differentiation of these two groups of women is important, since only persistent HPV infections can develop to cervical cancer [1,47], and this is enabled by our NGS assay with the inclusion and genotyping of all carcinogenic, probably carcinogenic, and possibly carcinogenic HPV types.…”

Section: Discussionmentioning

confidence: 99%

Targeted Next Generation Sequencing for Human Papillomavirus Genotyping in Cervical Liquid-Based Cytology Samples

Andersen

Holm

Tranberg

et al. 2022

Cancers

View full text Add to dashboard Cite

At present, human papillomavirus (HPV) testing is replacing morphology-based cytology as the primary tool for cervical cancer screening in several countries. However, the HPV assays approved for screening lack detection for all but one of the possibly carcinogenic HPV types and do not genotype all included HPV types. This study demonstrates the use of a targeted HPV next generation sequencing (NGS) panel to detect and genotype all 25 carcinogenic, probably carcinogenic, and possibly carcinogenic HPV types as well as the low-risk types HPV6 and HPV11. The panel was validated using a cohort of 93 paired liquid-based cytology samples (general practitioner (GP)-collected cervical samples and cervico-vaginal self-samples (SS)). Overall, the targeted panel had a sensitivity (GP = 97.7%, SS = 92.1%) and specificity (GP = 98.0%, SS = 96.4%) similar to the commercial HPV assays, Cobas® 4800 HPV DNA test (Roche) and CLART® HPV4S assay (GENOMICA). Interestingly, of the samples that tested positive with the NGS panel, three (6.4%) of the GP-collected samples and four (9.1%) of the self-samples tested positive exclusively for HPV types only included in the NGS panel. Thus, targeted HPV sequencing has great potential to improve the HPV screening programs since, as shown here, it can identify additional HPV positive cases, cases with HPV integration, variants in the HPV genome, and which HPV type is dominant in multi-infected cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeted Next Generation Sequencing for Human Papillomavirus Genotyping in Cervical Liquid-Based Cytology Samples

Andersen

Holm

Tranberg

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“… 17 , 18 Persistence is longer for high-risk than low-risk HPV types. 5 , 19 , 20 Only ~10% of all HPV infections persisting for several years were strongly associated with a high absolute risk of a precancer diagnosis. 21–23 …”

Section: Cervical Hpv Infection: Self-clearance and Persistencementioning

confidence: 99%

A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients

Kovachev

2021

IDR

View full text Add to dashboard Cite

The purpose of this review was to examine and summarize data for inosine pranobex (IP) immunotherapy in cervical HPV-positive patients. Persistent or recurring cervical human papillomavirus (HPV) infection is a major cause of cervical cancer. Self-clearance and blocking of cervical HPV infection depend on the status of the host immune system. Immunotherapy helps accelerate elimination of the infection. Host immunity is involved in the development of HPV infection. Several mechanisms of interaction between the virus and the immune system have been revealed; however, the mechanisms have not been completely elucidated. A properly functioning immune system impedes HPV progress and helps clear the pathogen from the body. IP has antiviral efficacy because it modulates both cellular and humoral immunities. IP has been on the market since 1971. Nevertheless, it has seldom been administered to treat cervical HPV infections. In this review, Google Scholar, PubMed/MEDLINE, Scopus, Cochrane Library, and Research Gate were searched for the period 1971–2021. Prospective controlled trials, observational and retrospective studies, and meta-analysis and reviews on immunotherapy against HPV cervical infection were explored. Prior studies showed strong clinical efficacy of combined and standalone IP therapy in reversing HPV-induced changes in the cervix, preventing disease progression, and clearing the pathogen. IP treatment enhanced host antiviral activity against HPV, delayed or stopped cervical oncogenesis, and rapidly removed HPV from the body.

show abstract

“…The Roche Diagnostics Linear Array test was employed. In this test, biotinylated PGMY09/11 consensus primers amplify a 450-bp region of the L1 gene: it is capable of detecting 37 HPV genotypes: HPV6, 11,16,18,26,31,33,35,39,40,42,45,51,52,53,54,55,56,58,59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), and IS39 e CP6108. The denatured PCR products were then hybridized to an array strip containing immobilized oligonucleotide probes.…”

Section: Linear Arraymentioning

confidence: 99%

“…The persistence of the genotype identified at baseline is helpful for stratifying the risk of CIN recurrence 9–11 …”

Section: Introductionmentioning

confidence: 99%

“…[6][7][8] The persistence of the genotype identified at baseline is helpful for stratifying the risk of CIN recurrence. [9][10][11] Anyplex II HPV HR (Anyplex; Seegene) is an HPV test with HR genotyping, which has been validated in accordance with Mejer's guidelines and the VALGENT-3 protocol and approved for screening. [12][13] However, no data has yet been published regarding its performance as a "test-of-cure" after treatment of CIN2+.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anyplex II HPV test in detection and follow‐up after surgical treatment of CIN2+ lesions

Bottari

Iacobone

Radice

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) tests differ for technology, targets, and information on the genotype and viral load. In this study, we evaluated the performance of the Seegene Anyplex II HPV HR (Anyplex) assay in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical treatment. One hundred and sixty-seven women referred to the European Institute of Oncology, Milan, for surgical treatment of CIN2+ were enrolled. A cervical sample was taken before treatment and at the first follow-up visit: on these samples, Qiagen Hybrid Capture 2 (HC2), Roche Linear Array HPV Test (Linear Array), cytology and histology were performed at baseline, HC2, and cytology at follow-up.Anyplex genotyping HPV test was performed on a post aliquot from liquid-based cytology specimens when available. The concordance between Anyplex and HC2 was 93.6% at baseline and 76.7% at follow-up (3-9 months after treatment), respectively. The concordance between Anyplex and Linear Array was evaluable only at baseline (92.9%). No recurrence occurred in women without the persistence of the same genotype at follow-up. Seven women relapsed: six had persistence of the same genotypes (five HPV16, one HPV33, and one HPV39), while one tested negative not only with Anyplex but also with HC2 for the persistence of low-risk genotype infection (HPV73 only detected by Linear Array). Anyplex test represents a valid option for HPV detection and genotyping in order to stratify women at risk of high-grade lesions at baseline and to monitor patients treated for CIN2+ lesions during follow-up.

show abstract

Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review

Abstract: Supplemental digital content is available in the text.

Cited by 25 publications

References 63 publications

Targeted Next Generation Sequencing for Human Papillomavirus Genotyping in Cervical Liquid-Based Cytology Samples

Targeted Next Generation Sequencing for Human Papillomavirus Genotyping in Cervical Liquid-Based Cytology Samples

A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients

Anyplex II HPV test in detection and follow‐up after surgical treatment of CIN2+ lesions

Contact Info

Product

Resources

About